Skip to main content

Research Repository

Advanced Search

Nanocrystallization Effectively Improves the Oral Efficacy of an Antileishmanial Chalcone

Borsodi, Maria Paula Gonçalves; Pacienza-Lima, Wallace; Menezes, Jaqueline Correia Villaça; Escrivani-Oliveira, Douglas; Arruda-Costa, Natalia; Silva, Alcides José Monteiro da; Cabral, Lucio Mendes; Steel, Patrick G.; Sousa-Batista, Ariane de Jesus; Rossi-Bergmann, Bartira

Nanocrystallization Effectively Improves the Oral Efficacy of an Antileishmanial Chalcone Thumbnail


Authors

Maria Paula Gonçalves Borsodi

Wallace Pacienza-Lima

Jaqueline Correia Villaça Menezes

Douglas Escrivani-Oliveira

Natalia Arruda-Costa

Alcides José Monteiro da Silva

Lucio Mendes Cabral

Ariane de Jesus Sousa-Batista

Bartira Rossi-Bergmann



Abstract

Background/Objectives: Cutaneous leishmaniasis (CL) is a vector-borne neglected disease that can cause permanent deformities. Current chemotherapy based on injections with toxic drugs or oral miltefosine poses many drawbacks, urging the need for new oral therapies. Here, we proposed to increase the bioavailability of NAT22, an intralesionally but not orally active antileishmanial chalcone, through nanocrystallization to promote its oral use in CL. Methods/Results: NAT22 nanocrystals were produced using a solvent-free green process of dry and wet milling that reduced NAT22 crystal sizes by around 1500-fold to 257 nm (nanoNAT22). Such reduction in size increased water solubility by 15-fold to 4.3 µg/mL and ensured stability in the absence of stabilizers for at least one month. Of note, nanoNAT22 in aqueous medium was more selective for parasites (SI = 35.2) than NAT22 in 1% DMSO (SI = 7.6). Leishmania amazonensis-infected mice treated with oral nanoNAT22 had lesion sizes and parasite loads similar to those achieved with intralesional Glucantime®, and significantly smaller than NAT22. Conclusions: Together, these results indicate that nanocrystallization is an effective process to render NAT22 chalcone also orally active against CL.

Citation

Borsodi, M. P. G., Pacienza-Lima, W., Menezes, J. C. V., Escrivani-Oliveira, D., Arruda-Costa, N., Silva, A. J. M. D., Cabral, L. M., Steel, P. G., Sousa-Batista, A. D. J., & Rossi-Bergmann, B. (2025). Nanocrystallization Effectively Improves the Oral Efficacy of an Antileishmanial Chalcone. Pharmaceutics, 17(4), Article 399. https://doi.org/10.3390/pharmaceutics17040399

Journal Article Type Article
Acceptance Date Mar 18, 2025
Online Publication Date Mar 21, 2025
Publication Date 2025-04
Deposit Date May 30, 2025
Publicly Available Date May 30, 2025
Journal Pharmaceutics
Electronic ISSN 1999-4923
Publisher MDPI
Peer Reviewed Peer Reviewed
Volume 17
Issue 4
Article Number 399
DOI https://doi.org/10.3390/pharmaceutics17040399
Keywords milling, leishmaniasis, chalcone, nanocrystals
Public URL https://durham-repository.worktribe.com/output/3789957

Files





You might also like



Downloadable Citations